BRIEF-Maplight Announces Topline Results From Phase 2 Iris Study For Ml-004 In Autism Spectrum Disorder

MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLT

0.00

June 22 (Reuters) - Maplight Therapeutics Inc MPLT.O:

  • MAPLIGHT ANNOUNCES TOPLINE RESULTS FROM PHASE 2 IRIS STUDY FOR ML-004 IN AUTISM SPECTRUM DISORDER

  • MAPLIGHT THERAPEUTICS - PHASE 2 IRIS TRIAL DOES NOT MEET PRIMARY ENDPOINT IN ASD

  • MAPLIGHT THERAPEUTICS - ML-004 GENERALLY WELL-TOLERATED WITH NO SEVERE OR SERIOUS ADVERSE EVENTS IN PHASE 2 IRIS TRIAL

  • MAPLIGHT THERAPEUTICS - TO ENGAGE WITH FDA IN END-OF-PHASE 2 MEETING FOR ML-004

Source text: ID:nGNXb7GH5X

Further company coverage: MPLT.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.